PMID- 33775972
OWN - NLM
STAT- MEDLINE
DCOM- 20211117
LR  - 20221207
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 68
IP  - 4
DP  - 2021 Apr 28
TI  - Angiotensin receptor blockers significantly reduce hemoglobin level in patients 
      with type 2 diabetes mellitus not suffered chronic cardiac failure and chronic 
      kidney disease.
PG  - 503-507
LID - 10.1507/endocrj.EJ20-0773 [doi]
AB  - Anemia due to angiotensin receptor blocker (ARB) therapy has been previously 
      reported in patients with diabetes mellitus with glomerular filtration rates of 
      <60 mL min(-1)/1.73 m(2). However, whether Japanese patients with type 2 diabetes 
      mellitus (T2DM) receiving ARB therapy for chronic cardiac failure and chronic 
      kidney disease develop reduced hemoglobin (Hb) levels has not been elucidated. 
      Thus, this cross-sectional study was conducted, and Hb levels were compared 
      between patients with T2DM with and without ARB administration. No significant 
      difference in the prescribed proportion of antidiabetic medicines such as 
      biguanide, sodium glucose co-transporter 2 inhibitors, and alpha-glucosidase 
      inhibitors was found between the group treated with ARBs and the group without 
      ARBs. Thus, we considered that the effects of antidiabetic medicines on the 
      results were minimum. In this study, the Hb levels of patients who received ARBs 
      (13.8 +/- 1.7 g/dL) were significantly lower than those of patients without ARBs 
      (14.9 +/- 1.35 g/dL) (p = 0.034). The difference between this study and a previous 
      study relies on eGFR levels. Thus, the eGFR levels of the patients in this study 
      and the previous study were above 60 and below 60 mL min(-1)/1.73 m(2), 
      respectively. Despite those differences, both studies showed that the use of ARBs 
      was associated with a decrease in Hb levels in patients with T2DM. Thus, the 
      evaluation of glycated Hb levels should be focused on whether ARBs are prescribed 
      for patients with T2DM.
FAU - Watanabe, Takuya
AU  - Watanabe T
AD  - Department of Endocrinology and Metabolism, Saku Central Hospital Advanced Care 
      Center, Nagano 385-0051, Japan.
FAU - Temma, Yuichi
AU  - Temma Y
AD  - Department of Endocrinology and Metabolism, Saku Central Hospital Advanced Care 
      Center, Nagano 385-0051, Japan.
FAU - Okada, Junichi
AU  - Okada J
AD  - Department of Medicine, Division of Endocrinology, Albert Einstein College of 
      Medicine, Bronx, NY 10461, USA.
FAU - Yamada, Eijiro
AU  - Yamada E
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma 371-8511, Japan.
FAU - Ishida, Emi
AU  - Ishida E
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma 371-8511, Japan.
FAU - Horiguchi, Kazuhiko
AU  - Horiguchi K
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma 371-8511, Japan.
FAU - Saito, Tsugumichi
AU  - Saito T
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma 371-8511, Japan.
FAU - Okada, Kazuya
AU  - Okada K
AD  - Omagari Kosei Medical Center, Akita 014-0027, Japan.
FAU - Takamizawa, Tetsuya
AU  - Takamizawa T
AD  - Department of Endocrinology and Metabolism, Saku Central Hospital Advanced Care 
      Center, Nagano 385-0051, Japan.
FAU - Nakajima, Yasuyo
AU  - Nakajima Y
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma 371-8511, Japan.
FAU - Ozawa, Atsushi
AU  - Ozawa A
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma 371-8511, Japan.
FAU - Okada, Shuichi
AU  - Okada S
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma 371-8511, Japan.
FAU - Horigome, Mitsuaki
AU  - Horigome M
AD  - Department of Endocrinology and Metabolism, Saku Central Hospital Advanced Care 
      Center, Nagano 385-0051, Japan.
FAU - Yamada, Masanobu
AU  - Yamada M
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma 371-8511, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210326
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin Receptor Antagonists/*pharmacology
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Glycated Hemoglobin/*analysis
MH  - Heart Failure/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Renal Insufficiency, Chronic/*blood
OTO - NOTNLM
OT  - Angiotensin receptor blocker
OT  - Glycated hemoglobin
OT  - Hemoglobin
OT  - Type 2 diabetes mellitus
EDAT- 2021/03/30 06:00
MHDA- 2021/11/18 06:00
CRDT- 2021/03/29 06:09
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2021/11/18 06:00 [medline]
PHST- 2021/03/29 06:09 [entrez]
AID - 10.1507/endocrj.EJ20-0773 [doi]
PST - ppublish
SO  - Endocr J. 2021 Apr 28;68(4):503-507. doi: 10.1507/endocrj.EJ20-0773. Epub 2021 
      Mar 26.